RALEIGH, N.C., March 19, 2012 /PRNewswire/ -- PRA, a leading Clinical Research Organization, announces that two of our Asia-Pacific leaders will speak at the BioPharma Asia Convention 2012 being held 19-22 March in Singapore. PRA will also host an exhibit at booth D7, where additional PRA representatives will be available to discuss our approach to clinical trials.
On 20 March at 12:10PM SGT, Dr. Kenneth Lee, PRA’s Senior Director of Scientific Affairs-Asia, will discuss his presentation, “Emerging Southeast Asia: A Glimpse into the Future.” Dr. Lee will review the key differentiators to consider when outsourcing to this region, best practices for leveraging unique sites, and requirements and strategies for creating a successful multi-country clinical trial framework.
That same day at 4:20PM SGT, PRA’s Helen Neal, Regional Director of Clinical Operations in Asia-Pacific, will participate in the panel discussion, “Determining your business strategy in Asia: Not one size fits all customizing solutions for different needs.” Ms. Neal and the other panelists will evaluate the region’s drug development environment, the financial and management risks that could jeopardize trial integrity, and the advantages of using a single CRO to manage clinical programs.
Dr. Lee is a cancer epidemiologist who has worked on a number of international healthcare projects with the World Health Organization (WHO), Harvard School of Public Health, and Johns Hopkins University. He received his M.D. from the National University of Singapore Faculty of Medicine and obtained a M.S. in epidemiology from the London School of Hygiene and Tropical Medicine, University of London. His broad industry experience encompasses clinical development and medical affairs across numerous indications and the product lifecycle throughout Asia.
In her current role at PRA, Ms. Neal focuses on ensuring the availability of appropriate and well-trained staff to resource projects, managing start-up processes, and providing quality deliverables to sponsors. With an educational background in nursing and midwifery, Ms. Neal has served in various positions of increasing responsibility in clinical operations and project management in the pharmaceutical and CRO industries since 1994. Her therapeutic experience includes cardiovascular, CNS, endocrinology, and infectious diseases across all phases.
Offering comprehensive trial coverage throughout Asia and surrounding territories, PRA has been strategically expanding our presence there since 2000. This year, we opened an office in Singapore, which serves as our regional operations hub. Additionally, PRA operates in eight other countries within the region: Korea, Taiwan, China, Hong Kong, Thailand, Australia, New Zealand, and India.
About PRA
PRA is transforming clinical trials through our people, innovation and transparency. PRA provides personalized service customized to the unique requirements of each study. We support our global reach and innovative approach through flexible and reliable service, delivered by skilled employees dedicated to ensuring that sponsors achieve their long-term goals.
We serve our clients across all phases of pharmaceutical and biotech drug development by combining therapeutic and operational expertise with local knowledge. Offering services in 80+ countries and serving sponsors for 30+ years, we have amassed a level of expertise that has enabled us to work on a variety of compounds, ranging from niche treatments and therapies to blockbuster drugs. But at PRA, we are looking to the future, not the past. Our increasingly forward-thinking approach to transforming the clinical trial landscape will continue to make a difference to healthcare patients around the world.
To learn more about PRA, please visit praintl.com, email endpoints@praintl.com or call our Global Headquarters.
SOURCE PRA
